Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Agenus Inc
(NQ:
AGEN
)
4.620
+0.050 (+1.09%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Agenus Inc
< Previous
1
2
3
4
Next >
AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit with the Schall Law Firm
September 09, 2024
From
The Schall Law Firm
Via
Business Wire
Rosen Law Firm Urges Agenus Inc. (NASDAQ: AGEN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
September 09, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
AGENUS INC. (NASDAQ: AGEN) INVESTOR ALERT: Investors With Large Losses in Agenus Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
September 09, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024
September 09, 2024
From
Agenus Inc.
Via
Business Wire
Agenus to Participate in September Investor Conferences
September 03, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Reports Second Quarter 2024 Operational and Financial Results
August 08, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Announces Appointment of Tom Harrison to Board of Directors
August 08, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers
August 07, 2024
From
Agenus Inc.
Via
Business Wire
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
July 26, 2024
From
Agenus Inc.
Via
Business Wire
AGEN Investors Have Opportunity to Join Agenus Inc. Securities Fraud Investigation with the Schall Law Firm
July 18, 2024
From
Schall Law Firm
Via
Business Wire
Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer
July 18, 2024
From
Agenus Inc.
Via
Business Wire
Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference
June 28, 2024
From
Agenus Inc.
Via
Business Wire
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
June 27, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
June 17, 2024
From
Agenus Inc.
Via
Business Wire
Nature Medicine Reports Agenus’ Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50
June 13, 2024
From
Agenus
Via
Business Wire
Agenus Announces Virtual Annual Shareholders Meeting
June 04, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2024
From
Agenus Inc.
Via
Business Wire
Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting
May 23, 2024
From
Agenus Inc.
Via
Business Wire
Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
May 23, 2024
From
Agenus Inc.
Via
Business Wire
FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer
May 16, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Reports First Quarter 2024 Results
May 07, 2024
From
Agenus Inc.
Via
Business Wire
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
May 07, 2024
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 01, 2024
From
Agenus Inc.
Via
Business Wire
Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting
April 24, 2024
From
Agenus Inc.
Via
Business Wire
Agenus to Provide First Quarter 2024 Financial Report and Corporate Update
April 23, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer
April 12, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Announces Reverse Stock Split of Common Stock
April 05, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Reports Fourth Quarter and Full Year 2023 Results
March 14, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024
March 06, 2024
From
Agenus Inc.
Via
Business Wire
Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From
Agenus Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.